메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Aditi Bhatt (Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India) Snita Sinukumar (Department of Surgical Oncology, Jehangir Hospital, Pune, India) Dileep Damodaran (Department of Surgical Oncology, MVR Cancer Center, Calicut, India) Loma Parikh (Department of Pathology, Zydus Hospital, Ahmedabad, India) Gaurav Goswami (Department of Radiology, Zydus Hospital, Ahmedabad, India) Sanket Mehta (Department of Surgical Oncology, Saifee Hospital, Mumbai, India) Praveen Kammar (Department of Surgical Oncology, Saifee Hospital, Mumbai, India)
저널정보
대한부인종양학회 Journal of Gynecologic Oncology Journal of Gynecologic Oncology Vol.35 No.4
발행연도
2024.7
수록면
1 - 15 (15page)
DOI
https://doi.org/10.3802/jgo.2024.35.e95

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Objective: The TORPEDO (CTRI/2018/12/016789) is the single-arm, prospective, inter ventionalstudy evaluating the role of a total parietal peritonectomy (TPP) in patients undergoing inter valcytoreductive surger y (iCRS). In this manuscript, we report the perioperative outcomes andplatinum resistant recurrence (PRR) in 218 patients enrolled in the study. Methods: A TPP was performed in all patients undergoing iCRS irrespective of the residualdisease extent. hyperthermic intraperitoneal chemotherapy (HIPEC) was performed as perthe clinician’s discretion with 75 mg/m2 of cisplatin. Maintenance therapy was also used atthe discretion of the treating clinicians. Results: From 9th December 2018 to 31st July 2022 (recruitment complete), 218 patients wereenrolled at 4 medical centers in India. The median surgical peritoneal cancer index was 14and a complete gross resection was achieved in 95.8%. HIPEC was performed in 130 (59.6%)patients. The 90-day major morbidity was 17.4% and 2.7% patients died within 90 days ofsurger y. Adjuvant chemotherapy was delayed beyond 6 weeks in 7.3%. At a median follow-up of 19 months (95% confidence inter val [CI]=15.9–35 months), 101 (46.3%) recurrencesand 19 (8.7%) deaths had occurred. The median progression-free sur vival was 22 months(95% CI=17–35 months) and the median overall sur vival (OS) not reached. Platinum resistantrecurrence was obser ved in 6.4%. The projected 3-year OS was 81.5% and in 80 patientstreated before may 2020, it was 77.5%. Conclusion: The morbidity and mortality of TPP with or without HIPEC performed duringiCRS is acceptable. The incidence was of PRR is low. Early sur vival results are encouraging andwarrant conduction of a randomized controlled trial comparing TPP with conventional surger y.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

최근 본 자료

전체보기

댓글(0)

0